Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
DNIB0600A (Lifastuzumab vedotin) is an antibody-drug conjugate consists of an antibody targeting SLC34A2 and monomethyl auristatin E, which may lead to disruption of the microtubule network in SLC34A2-expressing cancer cells, thereby potentially inhibiting cell proliferation (PMID: 29401246, PMID: 32534811, PMID: 31540980).
|CAS Registry Number||1401812-88-1|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Bevacizumab + Carboplatin + DNIB0600A||Bevacizumab Carboplatin DNIB0600A||0||1|
|Carboplatin + DNIB0600A||Carboplatin DNIB0600A||0||1|